Obesity and type 2 diabetes: can we find a compromised treatment solution?
Type 2 diabetes and obesity are two enormous epidemic diseases of the 21st century. Because obesity is a primary risk factor for type 2 diabetes development, patients with diabetes are frequently obese. This comorbidity makes it challenging for these patients to not only compensate diabetes...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/be86a836094944b6b85601c77ab36f29 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:be86a836094944b6b85601c77ab36f29 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:be86a836094944b6b85601c77ab36f292021-11-14T09:00:21ZObesity and type 2 diabetes: can we find a compromised treatment solution?2072-03512072-037810.14341/DM8726https://doaj.org/article/be86a836094944b6b85601c77ab36f292017-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/8726https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Type 2 diabetes and obesity are two enormous epidemic diseases of the 21st century. Because obesity is a primary risk factor for type 2 diabetes development, patients with diabetes are frequently obese. This comorbidity makes it challenging for these patients to not only compensate diabetes but also bring their weight back to normal. Several anti-diabetic drugs cause weight gain, which augments insulin resistance, and thus demands anti-diabetic treatment intensification. For the treatment, it is crucial to find an anti-diabetic treatment drug that is efficient but does not cause weight gain. In the last few decades, new anti-diabetic drugs with minimal or decrementing effects on the body weight have been introduced. New molecules appearing in the anti-obesity treatment are capable of not only reducing weight but also compensating diabetes. This study focuses on the current anti-obesity and anti-diabetic treatment and optimal combinations for treating comorbid patients.Gagik R. GalstyanEkaterina A. ShestakovaIgor A. SklyanikEndocrinology Research Centrearticletype 2 diabetes mellitusobesityantidiabetic drugsantiobesity drugsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 4, Pp 270-278 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
type 2 diabetes mellitus obesity antidiabetic drugs antiobesity drugs Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
type 2 diabetes mellitus obesity antidiabetic drugs antiobesity drugs Nutritional diseases. Deficiency diseases RC620-627 Gagik R. Galstyan Ekaterina A. Shestakova Igor A. Sklyanik Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| description |
Type 2 diabetes and obesity are two enormous epidemic diseases of the 21st century. Because obesity is a primary risk factor for type 2 diabetes development, patients with diabetes are frequently obese. This comorbidity makes it challenging for these patients to not only compensate diabetes but also bring their weight back to normal. Several anti-diabetic drugs cause weight gain, which augments insulin resistance, and thus demands anti-diabetic treatment intensification. For the treatment, it is crucial to find an anti-diabetic treatment drug that is efficient but does not cause weight gain. In the last few decades, new anti-diabetic drugs with minimal or decrementing effects on the body weight have been introduced. New molecules appearing in the anti-obesity treatment are capable of not only reducing weight but also compensating diabetes. This study focuses on the current anti-obesity and anti-diabetic treatment and optimal combinations for treating comorbid patients. |
| format |
article |
| author |
Gagik R. Galstyan Ekaterina A. Shestakova Igor A. Sklyanik |
| author_facet |
Gagik R. Galstyan Ekaterina A. Shestakova Igor A. Sklyanik |
| author_sort |
Gagik R. Galstyan |
| title |
Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| title_short |
Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| title_full |
Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| title_fullStr |
Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| title_full_unstemmed |
Obesity and type 2 diabetes: can we find a compromised treatment solution? |
| title_sort |
obesity and type 2 diabetes: can we find a compromised treatment solution? |
| publisher |
Endocrinology Research Centre |
| publishDate |
2017 |
| url |
https://doaj.org/article/be86a836094944b6b85601c77ab36f29 |
| work_keys_str_mv |
AT gagikrgalstyan obesityandtype2diabetescanwefindacompromisedtreatmentsolution AT ekaterinaashestakova obesityandtype2diabetescanwefindacompromisedtreatmentsolution AT igorasklyanik obesityandtype2diabetescanwefindacompromisedtreatmentsolution |
| _version_ |
1718429554476843008 |